Micafungin
ApprovedTerminated 0 watching 0 views this week๐ฅ Hot
85
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 2โ
Phase 35
ApprovedIndication / Disease
Candidemia
Conditions
Candidemia, Candidiasis
Trial Timeline
Sep 26, 2013 โ Aug 28, 2015
NCT ID
NCT01982071About Micafungin
Micafungin is a approved stage product being developed by Astellas Pharma for Candidemia. The current trial status is terminated. This product is registered under clinical trial identifier NCT01982071. Target conditions include Candidemia, Candidiasis.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (15)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03174457 | Pre-clinical | Completed |
| NCT03102658 | Approved | Completed |
| NCT02440178 | Phase 2 | Completed |
| NCT03421002 | Phase 2 | Completed |
| NCT02678598 | Pre-clinical | Completed |
| NCT02127788 | Pre-clinical | Completed |
| NCT02646800 | Approved | Terminated |
| NCT02646774 | Approved | Terminated |
| NCT02057289 | Phase 1 | Terminated |
| NCT01982071 | Approved | Terminated |
| NCT01135589 | Approved | UNKNOWN |
| NCT00606268 | Phase 1 | Completed |
| NCT00608335 | Phase 1 | Completed |
| NCT00818584 | Phase 1 | Completed |
| NCT00842504 | Phase 1 | Completed |
Competing Products
9 competing products in Candidemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| micafungin + Micafungin + Caspofungin | Astellas Pharma | Approved | 85 |
| AmBisome | Gilead Sciences | Approved | 84 |
| Anidulafungin/Fluconazole | Pfizer | Phase 3 | 76 |
| Anidulafungin + Voriconazole | Pfizer | Approved | 84 |
| Anidulafungin + Fluconazole | Pfizer | Phase 3 | 76 |
| Anidulafungin | Pfizer | Phase 3 | 76 |
| Fosmanogepix + Fosmanogepix + Caspofungin + Fluconazole + Placebo + Placebo + Placebo + Placebo | Basilea Pharmaceutica | Phase 3 | 72 |
| APX001 | Basilea Pharmaceutica | Phase 2 | 47 |
| APX001 | Basilea Pharmaceutica | Phase 2 | 47 |